VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice
- PMID: 17923114
- DOI: 10.1016/j.bbrc.2007.09.088
VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease resulting from motor neuron loss in the spinal cord and brain stem. In the present study, we found that systemic administration of recombinant vascular endothelial growth factor (VEGF) significantly diminished astrogliosis and increased the number of neuromuscular junctions in a Cu/Zn superoxide dismutase (SOD1) transgenic mouse model of ALS. Our results thus demonstrate a novel regulatory role of VEGF on astrocytes and are suggestive of protective effects of VEGF both in the peripheral and central nervous system in the SOD1 transgenic mouse model. These findings warrant further evaluation of the mechanism(s) of regulatory effects of VEGF on neuronal and non-neuronal cells, and the relation of these events to motor neuron degeneration and the onset and progression of ALS.
Similar articles
-
Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model.Brain. 2007 May;130(Pt 5):1289-305. doi: 10.1093/brain/awm043. Epub 2007 Apr 17. Brain. 2007. PMID: 17439986
-
Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice.Exp Biol Med (Maywood). 2011 Jan;236(1):91-8. doi: 10.1258/ebm.2010.010172. Epub 2010 Dec 16. Exp Biol Med (Maywood). 2011. PMID: 21163822
-
A dopamine receptor antagonist L-745,870 suppresses microglia activation in spinal cord and mitigates the progression in ALS model mice.Exp Neurol. 2008 Jun;211(2):378-86. doi: 10.1016/j.expneurol.2008.02.004. Epub 2008 Mar 4. Exp Neurol. 2008. PMID: 18423451
-
[Animal models of amyotrophic lateral sclerosis].Rinsho Shinkeigaku. 2007 Nov;47(11):934-7. Rinsho Shinkeigaku. 2007. PMID: 18210840 Review. Japanese.
-
VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS?Trends Mol Med. 2004 Jun;10(6):275-82. doi: 10.1016/j.molmed.2004.04.004. Trends Mol Med. 2004. PMID: 15177192 Review.
Cited by
-
Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?Front Neurosci. 2010 Jun 11;4:32. doi: 10.3389/fnins.2010.00032. Front Neurosci. 2010. PMID: 20592948 Free PMC article.
-
ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease.Front Neurosci. 2014 Aug 14;8:252. doi: 10.3389/fnins.2014.00252. eCollection 2014. Front Neurosci. 2014. PMID: 25177267 Free PMC article. Review.
-
Emerging roles for semaphorins and VEGFs in synaptogenesis and synaptic plasticity.Cell Adh Migr. 2012 Nov-Dec;6(6):541-6. doi: 10.4161/cam.22408. Epub 2012 Oct 17. Cell Adh Migr. 2012. PMID: 23076132 Free PMC article. Review.
-
Cellular and molecular mechanisms involved in the neuroprotective effects of VEGF on motoneurons.Front Cell Neurosci. 2013 Oct 21;7:181. doi: 10.3389/fncel.2013.00181. eCollection 2013. Front Cell Neurosci. 2013. PMID: 24155688 Free PMC article.
-
Bladder Regeneration Using a Polycaprolactone Scaffold with a Gradient Structure and Growth Factors in a Partially Cystectomized Rat Model.J Korean Med Sci. 2020 Oct 26;35(41):e374. doi: 10.3346/jkms.2020.35.e374. J Korean Med Sci. 2020. PMID: 33107231 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous